Browse > Article

Risk Factor for Recurrence in Completely Resected Stage IB Non-small Cell Lung Cancer  

Seok, Yang-Ki (Department of Thoracic and Cardiovascular Surgery, Kyungpook National University Hospital)
Lee, Eung-Bae (Department of Thoracic and Cardiovascular Surgery, Kyungpook National University Hospital)
Publication Information
Journal of Chest Surgery / v.40, no.10, 2007 , pp. 680-684 More about this Journal
Abstract
Background: Complete surgical resection is the most effective treatment for stage IB non-small cell lung cancer (NSCLC). Recurrence accounts for the disappointing survival rates after resection. There has been renewed interest in adjuvant therapy after complete resection. Appropriate selection of effective adjuvant therapy will depend on the prognostic factors for recurrence. Material and Method: The study included 114 patients with completely resected stage IB NSCLC. The variables selected for the study were gender, age, the type of resection, cell type, the degree of differentiation, the tumor size and the presence of visceral pleura invasion. The Kaplan-Meier method was used to estimate the survival and disease-free survival rate. The results were compared using the log rank test. Multivariate analysis was performed by Cox's proportional hazard model. Two-sided p-valves < 0.05 were considered to be statistically significant. Result: The 3-year overall survival and the disease-free survival rates were 87.0% and 79.4%, respectively. The degree of differentiation showed a significant influence on disease-free survival according to the univariate analysis. According to the multivariate analysis, a poor grade of differentiation was a significant poor prognostic factor. Conclusion: These results demonstrate that poor differentiation may be a poor prognostic factor for patients with completely resected IB NSCLC. Therefore, the patients with a poor grade of differentiation may require adjuvant therapies.
Keywords
Carcinoma, non-small cell, lung; Neoplasm recurrence; Neoplasm staging;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7   DOI   ScienceOn
2 Padilla J, Calvo V, Penalver JC, Sales G, Morcillo A. Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg 1997;63:324-6   DOI   ScienceOn
3 Padilla J, Calvo V, Penalver JC, et al. Survival and risk model for stage IB non-small cell lung cancer. Lung Cancer 2002;36:43-8   DOI   ScienceOn
4 Kang JH, Kim KD, Chung KY. Prognostic valve of visceral pleura invasion in non-small cell lung cancer. Eur J Cardiothorac Surg 2003;23:865-9   DOI   ScienceOn
5 Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion classification in non-small cell lung cancer: a proposal on the basis of outcome assessment. J Thorac Cardiovasc Surg 2004;127:1574-8   DOI   ScienceOn
6 Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-21   DOI   ScienceOn
7 Carbone E, Asamura H, Takei H, et al. T2 tumors larger than five centimeters in diameter can be upgraded to T3 in non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122:907-12   DOI   ScienceOn
8 Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60   DOI   PUBMED   ScienceOn
9 Ponn B, LoCicero III J, Daly BT. Surgical treatment of non-small cell lung cancer. In: Shields TW, Locicero III J, Ponn RB, Rusch VW. General thoracic surgery. 6th ed. Phiiladelphia: Wolters Kluver Co. 2005;1548-87
10 Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer. Chest 2002;122: 1037-57   DOI   ScienceOn
11 Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9   DOI   ScienceOn
12 Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001;71:1759-64   DOI   ScienceOn
13 Takeda S, Fukai S, Komatsu H, Nemoto E, Nakamura K, Murakami M. Impact of large tumor size on survival after resection of pathologically node negative (pN0) non-small cell lung cancer. Ann Thorac Surg 2005;79: 1142-6   DOI   ScienceOn
14 Cangir AK, Kutlay H, Akal M, Gungor A, Ozdemir N, Akay H. Prognostic value of tumor size in non-small cell lung cancer larger than five centimeters in diameter. Lung Cancer 2004;46:325-31   DOI   ScienceOn
15 Jones DR, Daniel TM, Denlinger CE, Rundall BK, Smolkin ME, Wick MR. Stage IB nonsmall cell lung cancers: are they all the same? Ann Thorac Surg 2006; 81:1958-62   DOI   ScienceOn
16 Lafitte JJ, Ribet ME, Prevost BM, Gosselin BH, Copin MC, Brichet AH. Postresection irradiation for T2N0M0 non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg 1996;62:830-4   DOI   ScienceOn
17 Ichinose Y, Hara N, Ohta M, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? J Thorac Cardiovasc Surg 1993;106:90-4   PUBMED